Cataflam

Contusions, Pain, Photophobia + 54 more

Treatment

10 FDA approvals

20 Active Studies for Cataflam

What is Cataflam

Diclofenac

The Generic name of this drug

Treatment Summary

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is used to reduce pain and inflammation. It works by blocking enzymes in the body that cause inflammation and pain. Diclofenac is often used as the first line of treatment for acute and chronic pain from a variety of sources. It is usually prescribed in combination with another drug, misoprostol, to prevent stomach ulcers caused by its use. Diclofenac was first approved by the FDA in 1988 and is sold under the brand name Voltaren.

Voltaren

is the brand name

image of different drug pills on a surface

Cataflam Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Voltaren

Diclofenac

1988

767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Osteoarthritis of the Knee and Pain .

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Pain

Helps manage Pain

Postoperative Inflammatory Response

Chronic Pain

Helps manage Pain

Osteoarthritis (OA)

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Stomach Ulcer

Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol

Osteoarthritis of the Knee

Used to treat Osteoarthritis of the Knee in combination with Capsaicin

Osteoarthritis

Used to treat Osteoarthritis (OA) in combination with Misoprostol

Rheumatoid Arthritis

Cataract Surgery

Effectiveness

How Cataflam Affects Patients

Diclofenac is used to reduce inflammation, pain, and fever. However, taking it can increase the risk of developing an ulcer in the stomach, since it reduces the amount of protective mucus produced.

How Cataflam works in the body

Diclofenac works by blocking enzymes that produce molecules called prostaglandins. Prostaglandins play a role in pain and inflammation. They make your body more sensitive to pain and reduce your immune response. Prostaglandins also widen your blood vessels, which can cause inflammation. By blocking these enzymes, the prostaglandins don't get made and inflammation can be reduced. In addition, diclofenac stops these molecules from triggering a fever.

When to interrupt dosage

The recommended amount of Cataflam is contingent upon the identified state, such as Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The dosage fluctuates in accordance with the technique of delivery (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) specified in the following table.

Condition

Dosage

Administration

Muscle Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Wounds, Nonpenetrating

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Contusions

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Photophobia

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Inflammation

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Fever

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Rheumatoid Arthritis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Surgery, Dental

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Conjunctivitis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

perioperative miosis

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Pain

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Rheumatism

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Postoperative Inflammatory Response

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Sprains and Strains

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Osteoarthritis of the Knee

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Musculoskeletal System

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Postoperative

100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg

, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops - Ophthalmic, Solution / drops, Liquid, Liquid - Topical, Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Ophthalmic, Rectal, Suppository - Rectal, Suppository, Solution - Topical, Tablet, Tablet - Oral, Kit, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule - Oral, Capsule, Cream, Cream - Topical, Transdermal, Solution / drops - Transdermal, Patch, Patch - Topical, Aerosol, metered, Aerosol, metered - Topical, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Powder - Oral, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system - Topical, Drug delivery system

Warnings

Cataflam Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Heart failure

Do Not Combine

Crohn's Disease

Do Not Combine

recent history of anal bleeding

Do Not Combine

Hemorrhagic Disorders

Do Not Combine

Gastritis

Do Not Combine

inflammatory lesions of the Rectum

Do Not Combine

active Gastrointestinal Bleeding

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

active Gastrointestinal Perforation

Do Not Combine

Duodenal Ulcer

Do Not Combine

Coronary Artery Bypass Grafting

Do Not Combine

Severe Hepatic Impairment

Do Not Combine

Ulcerative Colitis

Do Not Combine

Liver Diseases

Do Not Combine

Stroke

Do Not Combine

Third trimester of pregnancy

Do Not Combine

Hematochezia

Do Not Combine

Kidney Failure

Do Not Combine

Kidney Failure

Do Not Combine

Anus

Do Not Combine

Ulcer

Do Not Combine

damaged skin

Do Not Combine

Gastric ulcer

Do Not Combine

Peptic Ulcer

Do Not Combine

Hyperkalemia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Diclofenac may interact with Pulse Frequency

There are 20 known major drug interactions with Cataflam.

Common Cataflam Drug Interactions

Drug Name

Risk Level

Description

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Diclofenac.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.

Enasidenib

Major

The metabolism of Enasidenib can be decreased when combined with Diclofenac.

Erlotinib

Major

The metabolism of Erlotinib can be decreased when combined with Diclofenac.

Cataflam Toxicity & Overdose Risk

Overdosing on Voltaren can lead to symptoms such as tiredness, sleepiness, nausea, vomiting, and pain in the upper abdomen. In rare cases, patients may experience high blood pressure, kidney damage or failure, shallow breathing, or coma. Treatments for Voltaren overdose include inducing vomiting and activated charcoal, as long as the overdose occurred within the last 4 hours.

image of a doctor in a lab doing drug, clinical research

Cataflam Novel Uses: Which Conditions Have a Clinical Trial Featuring Cataflam?

491 active clinical trials are currently examining the potential of Cataflam to reduce Inflammation, facilitate Argon Laser Trabeculoplasty and ameliorate Osteoarthritis of the Knee.

Condition

Clinical Trials

Trial Phases

Inflammation

57 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 3

Osteoarthritis of the Knee

77 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Chronic Pain

116 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Early Phase 1, Phase 1

Rheumatoid Arthritis

56 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2, Phase 4

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Not Applicable, Phase 3

Dysmenorrhea

1 Actively Recruiting

Not Applicable

Muscle Pain

2 Actively Recruiting

Phase 4, Phase 2

Conjunctivitis

0 Actively Recruiting

Musculoskeletal System

1 Actively Recruiting

Not Applicable

corneal refractive surgery

0 Actively Recruiting

Postoperative Inflammatory Response

0 Actively Recruiting

Photophobia

5 Actively Recruiting

Not Applicable

Pain

2 Actively Recruiting

Not Applicable

Stomach Ulcer

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Juvenile arthritis

6 Actively Recruiting

Phase 2, Not Applicable, Phase 3

radial keratotomy

0 Actively Recruiting

Joints

0 Actively Recruiting

Pericarditis

2 Actively Recruiting

Phase 2, Phase 3

Acute Coryza

0 Actively Recruiting

Cataflam Reviews: What are patients saying about Cataflam?

5

Patient Review

10/10/2011

Cataflam for Painful Periods

Cataflam quickly and effectively alleviated the pain I was experiencing from my broken tooth.

5

Patient Review

3/4/2015

Cataflam for Pain

This really helped with my gum inflammation and tooth pain.

5

Patient Review

8/30/2017

Cataflam for Pain

I was in a lot of pain while on vacation, but this medication turned things around fast. I saw results after just two doses and felt better within 24 hours.

5

Patient Review

8/25/2012

Cataflam for Painful Periods

I'm not sure how effective this medication is because I take tramadol for pain relief.

5

Patient Review

6/10/2011

Cataflam for Pain

5

Patient Review

6/3/2022

Cataflam for Migraine Headache

This is my go-to treatment when I'm feeling stressed or have had too much wine. I drink it dissolved in a large glass of water and I'm good as new the next day.

4.7

Patient Review

9/15/2016

Cataflam for Pain

I have fibromyalgia and rheumatoid arthritis. I've been taking Ubuntu for years, and it works well for what it is. They changed my medication to this one because of severe headaches and dizziness, but it does not work! I hurt all over and am so tired - it's awful!

4

Patient Review

9/28/2013

Cataflam for Painful Periods

I was prescribed this to help with my endometriosis symptoms. The first pill did provide some relief, but after taking the second pill just a few hours later I felt incredibly nauseous. Not sure if the pain relief is worth the stomach upset.

3.7

Patient Review

10/27/2012

Cataflam for Migraine Headache

I've tried a lot of different medications for my chronic back and leg pain, and this one was just not effective at all.

3.3

Patient Review

8/17/2011

Cataflam for Rheumatoid Arthritis

The medication was prescribed to me for pain, but I only made it two days before having to stop. I developed intense stomach problems and weakness in my lower abdomen. After reading the side effects, I think this drug should be taken off the market. The negatives seem to outweigh any positives.

3.3

Patient Review

5/4/2013

Cataflam for Painful Periods

It would be helpful if there was a date on the article so readers know if the information is current. I stopped prescribing Cataflam because of the risk of heart attack.

3

Patient Review

6/29/2012

Cataflam for Pain

Even after taking both the cataflam 50mg and ibuprofen, my toothache pain has not subsided. I'm going to have to tough it out until I can see a dentist for a root canal.

2.7

Patient Review

4/28/2012

Cataflam for Pain

I've found this to be a little effective.

2.3

Patient Review

7/27/2012

Cataflam for Pain

Cataflam has been a saving grace for me. They provide much-needed relief when my condition gets bad and I can't leave home without them. Overall, they've really improved the quality of my life.

2.3

Patient Review

1/28/2011

Cataflam for Pain

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about cataflam

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of painkiller is Cataflam?

"Cataflam is a drug used to treat pain or inflammation caused by arthritis or ankylosing spondylitis. It is a nonsteroidal anti-inflammatory drug (NSAID)."

Answered by AI

Do you need a prescription for Cataflam?

"Cataflam is a medication used to relieve mild to moderate pain caused by conditions such as arthritis, menstrual cramps, and migraines. It can be taken alone or with other medications and belongs to a class of drugs called NSAIDs."

Answered by AI

What is a Cataflam used for?

"This medication is an NSAID, which stands for nonsteroidal anti-inflammatory drug. NSAIDs are used to relieve pain, swelling, and stiffness caused by various conditions such as muscle aches, backaches, dental pain, menstrual cramps, sports injuries, and arthritis. Reducing symptoms with an NSAID allows people to more easily do their normal daily activities."

Answered by AI

Who should not take Cataflam?

"Meningitis that is not caused by an infection, systemic mastocytosis, dehydration, hepatic porphyria, anemia, increased risk of bleeding due to clotting disorder, an increased risk of bleeding, and alcoholism can all lead to problems with the nervous system."

Answered by AI

Clinical Trials for Cataflam

Image of Alberta Children's Hospital in Calgary, Canada.

Therapeutic Cuddling for Pain in Critically Ill Children

< 65
All Sexes
Calgary, Canada

2.1 CONTEXT Pain and agitation are common comorbidities of pediatric critical illness due to both underlying disease processes and ICU related therapies. These are associated with both short and long term negative sequelae including increased mortality, length of stay, rates of ICU delirium, worse sleep, increased anxiety, depression, and chronic pain. The current standard of care to manage PICU associated pain and agitation is the use of analgosedation (e.g. opioids and benzodiazepines) these too are associated with increased time on the ventilator, length of stay, ICU delirium, and long term mental health and negative neuro-cognitive outcomes. Despite recommendations for increased use of non-pharmacologic therapies in the prevention and management of PICU associated pain, agitation, delirium, and analgosedation exposure, there are currently know therapies with clear evidence of efficacy. Therapeutic cuddling (e.g. kangaroo care, clothed cuddling, comfort holding, etc.) has been shown to decrease pain and anxiety in critically ill neonates, and healthy children and adults. Positive affective touch and hugging has known physiologic benefits and has been associated with decreased pain, improved immunity, and decreased mortality. Despite the potential for this intervention to aid in the prevention and management of PICU associated pain, agitation, delirium and analgosedation exposure, little data exists on efficacy of therapeutic cuddling in critically ill children. 2.2 OBJECTIVES 2.2.1 Primary Determine the feasibility of screening, consent, randomization, and retention of participants in a pragmatic RCT of therapeutic cuddling versus standard of care in the Alberta Children's Hospital Pediatric Intensive Care Unit. 2.2.2 Secondary 1. Determine treatment fidelity of participants randomized to the intervention arm. 2. Determine the prevalence of the therapeutic cuddling intervention in those randomized to the standard of care arm. 3. Determine the feasibility of measurement of key outcomes and co-variates (i.e., pain, agitation, sedation, delirium, analgosedation exposure, parental presence). 4. Describe the experience of patients, caregivers, and healthcare professionals in delivering/receiving the therapeutic cuddling intervention. 2.3 STUDY DESIGN Pilot feasibility randomized controlled trial of a structured co-designed therapeutic cuddling intervention as compared to the standard of care in a single tertiary care PICU. 2.4 DURATION 6 months to 1 year 2.5 LOCATION, DEPARTMENTS, AND FACILITY WHERE RESEARCH WILL BE UNDERTAKEN The pediatric intensive care unit at the Alberta Children's Hospital 2.6 SAMPLE SIZE A total sample size of 112 participants (56 per arm)

Recruiting
Has No Placebo

Alberta Children's Hospital

Image of University of Oklahoma Health Campus in Oklahoma City, United States.

Disulfiram for Rheumatoid Arthritis

18 - 75
All Sexes
Oklahoma City, OK

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and systemic immune activation. Obesity is common among individuals with RA and is associated with increased disease activity, reduced treatment response, and worse functional outcomes. Inflammation in adipose tissue, driven in part by activation of the NLRP3 inflammasome and downstream gasdermin D (GSDMD)-mediated pathways, may contribute to systemic inflammation and RA disease severity. Disulfiram (DSF), an FDA-approved medication for alcohol use disorder, has recently been identified as an inhibitor of GSDMD-mediated inflammatory signaling and pyroptosis. Preclinical studies suggest that DSF reduces inflammasome activation, inflammatory cytokine release, and metabolic dysfunction. This study is a 12-week, randomized, double-blind, placebo-controlled pilot trial designed to evaluate the safety, tolerability, and preliminary efficacy of DSF in overweight and obese adults with active RA despite stable disease-modifying antirheumatic drug (DMARD) therapy. Participants will be randomized to receive either DSF (250 mg daily) or placebo. The primary objective is to assess safety and tolerability. Secondary and exploratory objectives include evaluating the effects of DSF on systemic inflammation, RA disease activity, metabolic parameters, and adipose tissue inflammasome activation. Findings from this study will inform the feasibility and design of larger clinical trials targeting GSDMD-mediated inflammation in RA.

Phase 2
Waitlist Available

University of Oklahoma Health Campus

Beatriz Y Hanaoka, MD, MSc

Image of Hopital general de Montreal in Montreal, Canada.

Nurse-led Telehealth for Rheumatoid Arthritis

18+
All Sexes
Montreal, Canada

Canada urgently needs new ways to provide rheumatology care that improve treatment and make it easier for people to get high-quality care. E-health technology is a new and promising way to do this, but it hasn't been studied much yet in rheumatology. The investigators will test a new way to help people with rheumatoid arthritis at four clinics in Quebec. This study will check if the new approach is easy to use, fits well into the clinics' daily routine, and if both patients and healthcare workers find it helpful and acceptable. This new approach involves nurses helping patients check their own health from home using an online platform. 104 adults who have rheumatoid arthritis and who have had a flare-up or a change in their medication in the last three months, will participate. Some will start using the online self-monitoring tool right away for 16 months, while others will continue with their usual care for 8 months before trying the tool. During the time they use the tool, they will fill out monthly online questionnaires to check their health. A rheumatology nurse will review their answers, suggest any needed care, provide personalized health information, and be available to answer questions through messages. This new way of care, where nurses help patients monitor their rheumatoid arthritis from home, helps make better use of limited specialist time. It's more convenient for patients, especially those who live far away, and helps meet their needs between regular doctor visits while keeping the quality of care high.

Waitlist Available
Has No Placebo

Hopital general de Montreal (+3 Sites)

Laetitia Michou, MD PhD

Have you considered Cataflam clinical trials?

We made a collection of clinical trials featuring Cataflam, we think they might fit your search criteria.
Go to Trials
Image of University of California, Riverside in Riverside, United States.

Acetazolamide for Altitude Sickness

18 - 65
All Sexes
Riverside, CA

High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.

Phase < 1
Waitlist Available

University of California, Riverside

Have you considered Cataflam clinical trials?

We made a collection of clinical trials featuring Cataflam, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Epidural Steroid Injections for Back Pain

Any Age
All Sexes
Chicago, IL

Back pain is the leading cause of disability and military medical boards across the globe. Epidural steroid injections (ESI) are the most commonly performed pain procedure in the world. There is strong evidence that the placebo effect for all pain treatments, including ESI, is greater than the intrinsic effect. The placebo effect is highly dependent on a patient's 'expectations', and therefore how the procedure is framed. This study aims to compare ESI when the procedure is framed very positively- as is often done in clinical practice vs. more neutrally (which is less commonly done in clinical practice but consistent with evidence). The placebo effect is also stronger for procedures than medications. The evidence on the benefits of ESI is highly dependent on whether it is compiled by interventional doctors who perform the procedure or non-interventional researchers. In order to determine how 'framing' a treatment affects pain outcomes, the investigative team will conduct a 3-arm randomized trial comparing positive framing of ESI, neutral framing of ESI, and medications, in patients with lumbosacral radiculopathy.

Recruiting
New This Month

Northwestern University (+1 Sites)

Steven P Cohen, MD

Image of University of Miami in Miami, United States.

Steroid Injections for Radiating Back Pain

18+
All Sexes
Miami, FL

This study aims to evaluate the efficacy of interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, to evaluate the efficacy of interlaminar steroid injections at improving quality of life and function in lumbar radiculopathy at varying doses, and to evaluate difference in efficacy between triamcinolone and dexamethasone interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, with the overarching hypotheses that there is no difference in reported pain reduction, quality of life, or function among patients receiving low, moderate, or high doses, and no difference in reported pain reduction between triamcinolone and dexamethasone.

Phase 4
Waitlist Available

University of Miami

Seyed A mostoufi, MD

Have you considered Cataflam clinical trials?

We made a collection of clinical trials featuring Cataflam, we think they might fit your search criteria.
Go to Trials